GB301

GB301 is a recombinant human granulocyte colony-stimulating factor (rhG-CSF) developed by VTR Biotech, currently being investigated for the treatment of Alzheimer's disease. As a biosimilar candidate of filgrastim, GB301 functions as an agonist of the granulocyte colony-stimulating factor receptor (G-CSFR). In neurodegenerative contexts, G-CSF is hypothesized to provide therapeutic benefits by crossing the blood-brain barrier to promote neurogenesis, inhibit neuronal apoptosis, and mobilize hematopoietic stem cells from the bone marrow to the brain. These mobilized cells may assist in the clearance of amyloid-beta plaques and help modulate the neuroinflammatory environment. A Phase 1 clinical trial (NCT03944824) has been conducted to assess the safety, tolerability, and pharmacokinetics of GB301 following intravenous administration in patients with mild to moderate Alzheimer's disease.

Other names

recombinant human granulocyte colony-stimulating factorrhG-CSFfilgrastim